Evidence map›Paper›PMID 41039888›Full record

Observational studyActa dermato-venereologica2025

Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations.

Niccolo Gori, Alvise Sernicola, Elena Ippoliti, Rosa Coppola, Martina Maurelli, Michela Ortoncelli, Claudia Paganini, Ersilia Tolino, Maria Mariano, Ester Del Duca and 11 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Niccolo Gori *Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. niccolo.gori@unicatt.it.
Alvise Sernicola *Dermatology Unit, Department of Medicine (DIMED), University of Padua, Padova, Italy.
Elena IppolitiDermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Rosa CoppolaDermatologia, Fondazione Policlinico, Universitario Campus Bio-Medico, Roma, Italy.
Martina MaurelliSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Michela OrtoncelliDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
Claudia PaganiniDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
Ersilia TolinoDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Italy.
Maria MarianoSan Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Ester Del DucaDermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Gaia MorettaDepartment of Dermatology, Istituto Dermopatico dell'Immacolata -IRCCS, Dermatological Research Hospital, Rome, Italy.
Vincenzo PanasitiDermatologia, Fondazione Policlinico, Universitario Campus Bio-Medico, Roma, Italy.
Giampiero GirolomoniSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Simone RiberoDepartment of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
Luisa BoetiDermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Luca BianchiDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.
Maria Concetta FargnoliSan Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Giovanni PellacaniDermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.
Sabatino PallottaDepartment of Dermatology, Istituto Dermopatico dell'Immacolata -IRCCS, Dermatological Research Hospital, Rome, Italy.
Ketty PerisDermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Marco GalluzzoDepartment of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.

Indexed as

Antibodies, Monoclonal, HumanizedDermatitis, AtopicDermatologic AgentsAdolescentAdultAgedComorbidityFemaleHumansMaleMiddle AgedPatient Reported Outcome MeasuresSeverity of Illness IndexTime FactorsTreatment OutcomeYoung AdultAntibodies, Monoclonal, HumanizedDermatologic Agentsdupilumab

Identifiers

PMID41039888
PMCPMC12504992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.